What drugs commonly interact with ivermectin to cause toxicity?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin’s most concerning interactions involve drugs that either depress the central nervous system (CNS) or inhibit CYP3A4/P‑glycoprotein—raising ivermectin levels and permitting CNS penetration; examples cited in clinical reports include benzodiazepines, barbiturates, HIV protease inhibitors (and ritonavir/cobicistat boosters), certain calcium‑channel blockers, statins and warfarin (reports of increased INR) [1] [2] [3] [4] [5]. Clinical surveillance and drug references list many possible interactors (Drugs.com notes 106 interactions), so risk depends on the specific drug, dose, and patient factors [6] [7].
1. How interactions translate into toxicity — two main mechanisms
There are two recurrent pharmacologic mechanisms cited in the literature that can produce ivermectin‑related harm: pharmacodynamic potentiation of CNS depression (co‑use with benzodiazepines or barbiturates increases sedation, respiratory depression and overdose risk) and pharmacokinetic inhibition of ivermectin clearance or efflux (CYP3A4 inhibitors and P‑glycoprotein [P‑gp/MDR1] inhibitors can raise systemic and CNS ivermectin concentrations) [1] [2] [3].
2. CNS‑depressant drugs: immediate, clinically observable danger
Regulatory and clinical advisories specifically warn that ivermectin may make other CNS‑depressant drugs “more potent,” and identify benzodiazepines and barbiturates as concrete examples tied to increased risk of overdose manifestations such as decreased consciousness, confusion, seizures and coma [1]. Case series of neurologic adverse events also report benzodiazepine co‑use among affected patients [2].
3. CYP3A4 and P‑glycoprotein inhibitors: a pathway to unexpected neurotoxicity
Multiple reviews and case reports link increased ivermectin exposure—and hence neurologic events—to co‑administration with CYP3A4 substrates/inhibitors and drugs that inhibit P‑gp. Reported co‑medications include HIV protease inhibitors (notably ritonavir and cobicistat boosters), certain macrolide antibiotics and azole antifungals (example drugs named in secondary sources include erythromycin and ketoconazole), and verapamil among calcium‑channel blockers; these medications can raise ivermectin blood levels or reduce its efflux at the blood‑brain barrier, facilitating CNS entry [2] [3] [8] [5].
4. Statins, calcium‑channel blockers and case‑series signals
Clinical case reviews note simultaneous use of statins and calcium‑channel blockers among patients with ivermectin‑linked neurologic events, suggesting these frequently‑used drug classes may be implicated when combined with ivermectin—either through shared transporter relationships or via CYP‑mediated effects—though causality in every case is not established [2] [3].
5. Anticoagulants and other clinically relevant interactions
Post‑marketing reports and prescribing information flag a possible interaction with warfarin: rare reports describe increased INR when warfarin and ivermectin were co‑administered, implying potential for enhanced anticoagulant effect and bleeding risk [4] [5]. Clinical resources also warn that alcohol can increase certain side effects such as sleepiness and dizziness [9] [10].
6. Scope: many potential interactors, but signal strength varies
Drug interaction databases list large numbers of potential interactions (Drugs.com cites 106 drugs) and patient resources (Mayo Clinic, WebMD, Drugs.com) treat ivermectin as a medicine that can interact with many prescription, OTC and herbal products; however, the strongest clinical signal in case reports concerns CNS depressants and agents that increase ivermectin exposure via CYP3A4/P‑gp pathways [6] [7] [9].
7. What the reporting does and does not prove
Case series and pharmacology reviews document associations and plausible mechanisms (P‑gp inhibition, CYP3A4 inhibition and additive CNS depression), but do not prove universal causation for every listed drug; some sources call for further investigation into host factors (for example, MDR1 polymorphisms, co‑infections like Loa loa, or blood‑brain barrier compromise) that might determine who develops severe toxicity [2] [3].
8. Practical takeaways for clinicians and patients
Clinical advisories urge caution: avoid unsupervised ivermectin use, review all co‑medications for CNS depressants and CYP3A4/P‑gp inhibitors, and monitor closely if co‑use is unavoidable (noting INR if on warfarin, and vigilance for neurosedation). Public health notices emphasize that ivermectin is not authorized for COVID‑19 and improper use has driven hospitalizations [1] [11].
Limitations: available sources do not list every interacting drug individually; databases (Drugs.com, DrugBank, Medscape) enumerate interactions and provide clinical management guidance but strength of evidence differs by drug and report [6] [12] [5].